Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

The role of antidepressants in the management of inflammatory bowel disease (IBD): a short report on a clinical case-note audit.

Mikocka-Walus AA, Gordon AL, Stewart BJ, Andrews JM.

J Psychosom Res. 2012 Feb;72(2):165-7. doi: 10.1016/j.jpsychores.2011.06.006. Epub 2011 Jul 29.

PMID:
22281460
2.
3.

Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics.

Haapamäki J, Tanskanen A, Roine RP, Blom M, Turunen U, Mäntylä J, Färkkilä MA, Arkkila PE.

Scand J Gastroenterol. 2013 Jan;48(1):42-50. doi: 10.3109/00365521.2012.743584. Epub 2012 Nov 19.

PMID:
23163864
4.

Attitudes towards antidepressants among people living with inflammatory bowel disease: an online Australia-wide survey.

Mikocka-Walus A, Andrews JM.

J Crohns Colitis. 2014 Apr;8(4):296-303. doi: 10.1016/j.crohns.2013.09.002. Epub 2013 Sep 26.

PMID:
24074632
6.

[Antidepressants consumption in the global population in France].

Olié JP, Elomari F, Spadone C, Lépine JP.

Encephale. 2002 Sep-Oct;28(5 Pt 1):411-7. French.

PMID:
12386542
7.
8.

Chronic sinonasal disease in patients with inflammatory bowel disease.

Book DT, Smith TL, McNamar JP, Saeian K, Binion DG, Toohill RJ.

Am J Rhinol. 2003 Mar-Apr;17(2):87-90.

PMID:
12751702
9.
10.

Antidepressants in Inflammatory Bowel Disease: A Systematic Review.

Macer BJ, Prady SL, Mikocka-Walus A.

Inflamm Bowel Dis. 2017 Apr;23(4):534-550. doi: 10.1097/MIB.0000000000001059. Review.

PMID:
28267046
11.

Impact of sleep disturbances in inflammatory bowel disease.

Ranjbaran Z, Keefer L, Farhadi A, Stepanski E, Sedghi S, Keshavarzian A.

J Gastroenterol Hepatol. 2007 Nov;22(11):1748-53.

PMID:
17914945
12.

Impact of autonomic dysfunction on inflammatory bowel disease.

Ananthakrishnan AN, Issa M, Barboi A, Jaradeh S, Zadvornova Y, Skaros S, Johnson K, Otterson MF, Binion DG.

J Clin Gastroenterol. 2010 Apr;44(4):272-9. doi: 10.1097/MCG.0b013e3181b2682a.

PMID:
19727003
13.

Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.

Waters H, Vanderpoel J, McKenzie S, Lunacsek O, Franklin M, Lennert B, Goff J, Augustyn DH.

J Med Econ. 2011;14(4):397-402. doi: 10.3111/13696998.2011.583152. Epub 2011 May 19.

PMID:
21595522
14.

Are patients with inflammatory bowel disease receiving optimal care?

Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA.

Am J Gastroenterol. 2005 Jun;100(6):1357-61.

PMID:
15929770
15.

An initial report of sleep disturbance in inactive inflammatory bowel disease.

Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM, Keshavarzian A.

J Clin Sleep Med. 2006 Oct 15;2(4):409-16.

PMID:
17557469
16.

Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease.

Moser G, Tillinger W, Sachs G, Genser D, Maier-Dobersberger T, Spiess K, Wyatt J, Vogelsang H, Lochs H, Gangl A.

Eur J Gastroenterol Hepatol. 1995 Sep;7(9):853-8.

PMID:
8574717
17.

Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.

Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW.

Am J Gastroenterol. 1999 Nov;94(11):3248-53.

PMID:
10566724
18.

Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey.

Hilsden RJ, Verhoef MJ, Best A, Pocobelli G.

Am J Gastroenterol. 2003 Jul;98(7):1563-8.

PMID:
12873578
19.

The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study.

Ott C, Obermeier F, Thieler S, Kemptner D, Bauer A, Schölmerich J, Rogler G, Timmer A.

Eur J Gastroenterol Hepatol. 2008 Sep;20(9):917-23. doi: 10.1097/MEG.0b013e3282f97b33.

20.

Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.

Pearce CB, Lawrance IC.

J Gastroenterol Hepatol. 2007 Oct;22(10):1671-7.

PMID:
17845695

Supplemental Content

Support Center